ULTRAGENYX PHARMACEUTI

Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update

25 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium

24 Jul 2024 08:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program

17 Jul 2024 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 Jun 2024 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

13 Jun 2024 20:49:09 By Nasdaq GlobeNewswire

Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

12 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)

12 Jun 2024 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)

11 Jun 2024 17:47:59 By Nasdaq GlobeNewswire

Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference

04 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

30 May 2024 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

17 May 2024 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference

07 May 2024 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

02 May 2024 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease

30 Apr 2024 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

30 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update

25 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102

15 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome

12 Apr 2024 16:22:53 By Nasdaq GlobeNewswire